FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting

FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting

Source: 
Endpoints
snippet: 

The FDA has placed a clinical hold on Neoleukin’s IND application for NL-201, a de novo cytokine receptor agonist for IL-2 and IL-15, which it hoped to test in expanding CD8 T cells and natural killer cells for use in oncologic therapeutic areas, the company said Friday.